PT Kalbe Farma Unsponsored Indonesia ADR (PTKFY) – aksjekurser og nyheter

PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia

Om PT Kalbe Farma Unsponsored Indonesia ADR

Administrerende direktør-

Ansatte12,8k

Grunnlagt10. sep. 1966

Hovedkontor-

Sektor-

Nettstedkalbe.co.id

Alle verdier i IDR	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	8,91 bill.	9,34 bill.	9,68 bill.	9,80 bill.
Varekostnad	5,46 bill.	5,92 bill.	6,02 bill.	6,25 bill.
Direkte driftskostnader	5,46 bill.	5,92 bill.	6,02 bill.	6,25 bill.
Utgifter til forskning og utvikling	98,31 mrd.	160,88 mrd.	113,14 mrd.	122,60 mrd.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	2,51 bill.	1,95 bill.	2,23 bill.	2,27 bill.
Driftskostnader	2,60 bill.	2,14 bill.	2,33 bill.	2,39 bill.
Totale driftskostnader	8,06 bill.	8,05 bill.	8,36 bill.	8,64 bill.
Driftsinntekter	851,77 mrd.	1,28 bill.	1,32 bill.	1,16 bill.
Andre ikke-operasjonelle inntekter	−3,78 mrd.	−4,17 mrd.	−3,63 mrd.	−3,74 mrd.
EBT inkludert uvanlige elementer	877,87 mrd.	1,30 bill.	1,36 bill.	1,19 bill.
EBT uten uvanlige elementer	888,55 mrd.	1,30 bill.	1,36 bill.	1,18 bill.
Kostnad for inntektsskatt	211,19 mrd.	252,81 mrd.	303,84 mrd.	271,57 mrd.
Faktisk avgiftssats	24,06 %	19,41 %	22,40 %	22,80 %
Andre driftskostnader	−7,23 mrd.	31,35 mrd.	−10,02 mrd.	2,13 mrd.
Nettoinntekt	656,41 mrd.	1,03 bill.	1,03 bill.	890,54 mrd.
Netto fortjenestemargin	7,37 %	11,07 %	10,63 %	9,09 %
Resultat per aksje	14,44	22,72	22,74	19,68
Rente- og investeringsinntekter	41,31 mrd.	40,43 mrd.	32,07 mrd.	43,61 mrd.
Rentekostnader	−9,69 mrd.	−5,77 mrd.	−4,61 mrd.	−6,78 mrd.
Netto rentekostnader	31,62 mrd.	34,66 mrd.	27,46 mrd.	36,83 mrd.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	1,05 bill.	1,45 bill.	1,51 bill.	1,20 bill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

Finance

Spør om hva som helst